John Canale, MD
Psychiatry · O Fallon, MONPI 1578569620
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 992 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 9.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 992 payments — averaging $15.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $8K from 30 others
Across 478 payments — averaging $2247.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$401K
- Eisai Inc.$264K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$241K
- AbbVie$89K
- Avanir Pharmaceuticals, Inc.$33K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$29K
- plus $16K from 1 others
What the payments were for
- Travel & lodging$170%
- Food & beverage$15,66699%
- Education$811%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$181
How this compares
$15,764 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 20 | $223,137 |
| IngrezzaValbenazine Tosylate | 25 | $212,036 |
| VraylarCariprazine Hcl | 36 | $57,335 |
| CaplytaLumateperone Tosylate | 27 | $43,514 |
| AuvelityDextromethorphan Hbr/Bupropion | 36 | $40,737 |
| Aripiprazole | 222 | $18,954 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,231 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 334 | $16,197 |
| LatudaLurasidone Hcl | 11 | $16,047 |
| Lurasidone Hcl | 47 | $15,500 |
| TrintellixVortioxetine Hydrobromide | 19 | $14,306 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 457 | $12,635 |
| Duloxetine Hcl | 587 | $11,519 |
| Asenapine Maleate | 15 | $10,554 |
| Bupropion XlBupropion Hcl | 415 | $9,123 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Loxapine | $1,003 | $224,60539 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,185 | $212,03625 claims |
| AbbVieVraylar | $1,499 | $57,33536 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $894 | $43,51427 claims |
| Axsome Therapeutics, Inc.Auvelity | $567 | $40,73736 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $189 | $18,23112 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $1,302 | $16,04711 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $926 | $14,30619 claims |
| MerckBelsomra | $243 | $7,09717 claims |
| Almatica Pharma LLCSertraline Hcl | $88 | $1,403293 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in O Fallon
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
- Ahmed TaranissiMexico$343K
- Ravdeep KhanujaPoplar Bluff$310K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.